Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Projected to Grow at 18.5% CAGR, Reaching $4.17 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Ribonucleic Acid (RNA)-Based Oncolytic Therapy Industry Market Size Be by 2025?
The oncology market, specifically in the realm of RNA-based oncolytic therapies, has experienced substantial growth in recent years; with its market size expected to rise from $1.78 billion in 2024 to $2.12 billion in 2025. This upturn represents a compound annual growth rate (CAGR) of 18.9%. Factors contributing to this historic growth include the escalation in cancer rates, increased investments in healthcare facilities, growing consciousness about targeted treatments, the broadening of clinical trial initiatives, and a surge in government funding for cancer research.

What's the Long-Term Growth Forecast for the Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Size Through 2029?
The market for ribonucleic acid (RNA)-based oncolytic therapy is anticipated to expand rapidly in the upcoming years, reaching $4.17 billion in 2029 with an 18.5% compound annual growth rate (CAGR). This growth during the prediction period is largely due to the growing acceptance of RNA-based treatments, enhanced attention towards immuno-oncology, increasing biotechnology partnerships, the continued expansion of sophisticated manufacturing facilities, and increased availability of precision medicine. The forthcoming period will also witness significant trends such as technological progress, advancements in viral vector design, research and development investments, innovation in delivery systems, and the evolution of combination therapy strategies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/ribonucleic-acid-rna-based-oncolytic-therapy-global-market-report

What Are the Key Growth Drivers Fueling the Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Expansion?
The surge in personalized medicine usage is anticipated to drive the expansion of the RNA-based oncolytic therapy market. Personalized medicine relates to treatments specifically designed for individual genetic profiles, enhancing the effectiveness and minimizing undesirable impacts. More health service providers and institutions are employing personalized medicine, recognizing its capability to improve patient results via precise diagnostics and targeted treatments. RNA-based oncolytic therapy significantly contributes to cancer treatment by integrating with the rising adoption of personalized medicine, thereby providing patient-specific and focused treatment methods. For instance, in February 2024, the Personalized Medicine Coalition, a US-based advocate for customized medical treatments, and the FDA authorized 16 new personalized treatments for rare disease patients in 2023, a significant increase from the 6 approved in 2022. Therefore, the increasing uptake of personalized medicine is propelling the RNA-based oncolytic therapy market forward.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28321&type=smp

What Are the Key Trends Driving Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Growth?
In the ribonucleic acid (RNA)-based oncolytic therapy market, numerous leading corporations are emphasizing the creation of innovative technologies like synthetic messenger RNA (mRNA) technology to escalate the efficacy of tumor-targeting, foster immune activation, and procure precise and long-lasting results in cancer therapy. Synthetic messenger RNA (mRNA) technology is a biotechnological method by which lab-concocted mRNA sequences are crafted and dispatched to command cells to generate particular therapeutic proteins for disease curing, including cancer. For instance, in June 2024, CSPC Pharmaceutical Group Limited, a pharmaceutical firm based in China, got regulatory sanction in China to commence clinical trials for SYS6020, its synthetic mRNA-centric cancer cell therapy. This novel progression signifies a significant leap in China's messenger RNA therapeutic industry. SYS6020 utilizes mRNA-lipid nanoparticle technology to specifically aim at and eradicate myeloma cancer cells with minimal side effects, while also exhibiting possible uses in handling specific autoimmune disorders.

How Is the Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Segmented?
The ribonucleic acid (RN)-based oncolytic therapy market covered in this report is segmented as

1) By Therapy Type: Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy, Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy, Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy, Other Therapy Types
2) By Route Of Administration: Intravenous, Intratumoral, Other Route Of Administrations
3) By Application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Applications
4) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics, Other End-Users

Subsegment:
1) By Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy: Self-Amplifying mRNA (saRNA), Non-Replicating mRNA, Circular RNA (circRNA)-Based mRNA therapy
2) By Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy: Chemically Modified siRNA, Nanoparticle-Delivered siRNA, Conjugated siRNA
3) By Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy: miRNA Mimics, miRNA Inhibitors (Antagomirs), miRNA Aponges Or Decoys
4) By Other Therapy Types: Long Non-Coding RNA (lncRNA)-Based Therapies, Short Hairpin RNA (shRNA)-Based Therapies, Aptamer-RNA Based Oncolytic Agents

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28321&type=smp

Which Companies Are Leading the Charge in Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Innovation?
Major companies operating in the ribonucleic acid (rna)-based oncolytic therapy market are AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.

Which Regions Are Leading the Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market in Revenue?
North America was the largest region in the ribonucleic acid (RNA)-based oncolytic therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ribonucleic acid (RNA)-based oncolytic therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28321

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay,
Americas: +1 310-496-7795,
Asia: +44 7882 955267 & +91 8897263534,
Europe: +44 7882 955267,
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.